2026 Society for Neuro-Oncology Annual Meeting

ABSTRACTS

SERVIER

ABSTRACTS

2026 Society for Neuro-Oncology Annual Meeting

SERVIER

Title	Presentation
NOVEMBER 13 | 7:30–9:30 PM EST One-year compliance to vorasidenib among patients with IDH-mutant glioma: real-world evidence from the GLIO-ADHERE study	**POSTER SESSION** **Qingqing Xu** *Servier Pharmaceuticals, LLC*
NOVEMBER 13 | 7:30–9:30 PM EST Vorasidenib study in pediatric participants with Grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation	**POSTER SESSION** **Kee Kiat Yeo** *Dana-Farber Cancer Institute*
NOVEMBER 13 | 7:30–9:30 PM EST Safety outcomes from Phase 1b/2 study of vorasidenib in combination with temozolomide in patients with high-grade mutant IDH1 or IDH2 glioma (IDHEAL 4U)	**POSTER SESSION** **Mehdi Touat** *Pitié Salpêtrière Hospital*
NOVEMBER 13 | 7:30–9:30 PM EST Incidence and prevalence of mIDH glioma in the U.S. corrected for missing data	**POSTER SESSION** **Quinn T. Ostrom** *Central Brain Tumor Registry of the United States & Duke University School of Medicine*
NOVEMBER 14 | 3:45–3:52 PM EST Updated 4-year results from the phase 2 FIREFLY-1 study: Clinical stability and durability of response to tovorafenib in relapsed/ refractory pediatric low-grade glioma	**ORAL PRESENTATION** **Daniel Landi** *Duke University*
NOVEMBER 14 | 5:00–5:07 PM EST Efficacy data and subgroup analyses after extended follow-up with vorasidenib in INDIGO - a global, randomized, placebo-controlled double-blinded, Phase 3 trial in grade 2 mutant isocitrate dehydro-genase 1/2 (mIDH1/2) glioma	**ORAL PRESENTATION** **Timothy F. Cloughesy** *University of California Los Angeles*
NOVEMBER 14 | 5:07–5:14 PM EST Real-world utilization and outcomes of vorasidenib-treated patients with grade 2 IDH-mutant gliomas in the US	**ORAL PRESENTATION** **Jennie W. Taylor** *University of California San Francisco*
NOVEMBER 14 | 5:14–5:21 PM EST Real-world utilization of vorasidenib among patients with grade 3 IDH-mutant gliomas in the US	**ORAL PRESENTATION** **Edina Komlodi-Pasztor** *MedStar Georgetown University Hospital*

NOVEMBER 15 | 11:07–11:14 AM EST

Impact of vorasidenib vs placebo on seizure rates and quality of life: exploratory analysis from Phase 3 INDIGO study

ORAL PRESENTATION

Wolfgang Wick

Universitätsklinikum Heidelberg & German Cancer Research Center

Independent Abstracts & Partnered Abstracts

NOVEMBER 13 | 7:30–9:30 PM EST

Clinical outcomes and predictors of early progression in IDH1/2-Mutant gliomas treated with vorasidenib: A multicentre real-world study from the Spanish RETSINE-GEINO registry

POSTER SESSION

Estela Pineda

Hospital Clinic Barcelona

NOVEMBER 13 | 7:30–9:30 PM EST

18F-AGX PET for evaluating Vorasidenib response and tumor metabolic changes in low-grade IDH-mutant glioma (EASTERN-18): A TRIAL-IN-PROGRESS

POSTER SESSION

Yulai Zeng

Huashan Hospital, Fudan University

NOVEMBER 13 | 7:30–9:30 PM EST

Vorasidenib as maintenance treatment after first-line chemo-radiotherapy in IDH-mutant grade 2/3 astrocytoma: study protocol for the ongoing placebo-controlled, triple-blind, randomized phase III study EORTC-2427 (VIGOR)

POSTER SESSION

Marjolein Geurts

Erasmus MC Cancer Institute